Middle East & Africa Regenerative Medicines Market Size and Forecast (2021 - 2031)
The regenerative medicine market in the Middle East and Africa (MEA) is poised for significant growth, with projections indicating that its size will expand from approximately US$ 216.4 million in 2024 to US$ 561.3 million by 2031. This growth trajectory reflects a compound annual growth rate (CAGR) of 14.5% from 2025 to 2031, highlighting the increasing demand for innovative medical solutions in the region.
Market Overview
The MEA regenerative medicine market is categorized into several key regions, including Saudi Arabia, the United Arab Emirates (UAE), South Africa, and the broader Rest of MEA segment. A major health concern in this region is diabetes, which affects around 73 million adults, as reported by the International Diabetes Federation (IDF) in 2021. Additionally, genetic disorders such as sickle cell anemia and beta-thalassemia are prevalent due to the region's diverse genetic background. The ongoing clinical trials for CRISPR-based therapies, such as those conducted by Bluebird Bio for sickle cell disease, underscore the potential for innovative treatments in this area.
Investment in the manufacturing capabilities for cell and gene therapies is on the rise, with both organizations and academic institutions actively engaging in research and development (R&D). Collaborations with Contract Development and Manufacturing Organizations (CDMOs) are becoming more common, bridging the gap between scientific discovery and market readiness.
Market Segmentation
The MEA regenerative medicines market can be segmented by product type, application, and region.
The integration of artificial intelligence (AI) into regenerative medicine is revolutionizing the field by enhancing drug discovery processes, personalizing therapies, and expediting development timelines. AI technologies are adept at managing complex biological data and optimizing manufacturing processes, which leads to more efficient regenerative therapies. For instance, Aspen Neuroscience's ANPD-001, currently in Phase II clinical trials for Parkinson's disease, exemplifies how AI can be utilized to reprogram patient skin cells into dopamine-producing neurons. This innovative approach not only ensures the quality of the cells through proprietary AI-based genomic tests but also enhances the safety and personalization of treatments.
Startups are also leveraging AI to advance regenerative medicine. For example, MesencHyal-T from Argentina employs AI-driven cellular therapies for bone regeneration, utilizing machine learning to standardize stem cell expansion and improve their osteogenic potential. Similarly, Trogenix from the UK integrates genomics and machine learning into its viral immunotherapy for targeted regenerative treatments in cancer and age-related tissue repair.
AI platforms are facilitating faster product launches and drug candidate generation. Insilico Medicine, a leader in AI drug discovery, has made headlines with INS018_055, the first entirely AI-discovered medication to enter Phase II trials. Their collaboration with Sanofi, valued at US$ 1.2 billion, showcases the potential of AI in identifying novel therapeutic targets and predicting clinical outcomes.
In manufacturing, companies like Shinobi Therapeutics are utilizing AI to develop immune-evasive induced pluripotent stem cell (iPSC) therapies, which are designed to evade immune detection. This innovation is crucial for creating off-the-shelf regenerative treatments for various conditions, including oncology and autoimmune disorders.
Regional Insights
The MEA regenerative medicines market is further segmented by country, with Saudi Arabia, the UAE, South Africa, and the Rest of MEA being key players. The Rest of MEA, which includes countries like Iran, Iraq, Kuwait, Qatar, Egypt, Kenya, and Israel, held the largest market share in 2024. The increasing prevalence of chronic and degenerative diseases in these nations is driving the demand for regenerative therapies, particularly stem cell treatments that address conditions such as cancer, diabetes, and cardiovascular diseases.
Israel, known for its advancements in biomedical research, is a leader in stem cell and gene therapies, supported by institutions like the Weizmann Institute and Technion. Qatar's focus on genomic research through the Qatar Genome Programme is also noteworthy, as it aims to identify genetic markers for diseases and facilitate the development of targeted therapies. Egypt is making strides in stem cell research, particularly for liver diseases, through institutions like Cairo University.
Conclusion
The regenerative medicine market in the Middle East and Africa is on the cusp of transformative growth, driven by technological advancements, increasing disease prevalence, and strategic collaborations. As the region continues to innovate and invest in regenerative therapies, it is well-positioned to address the healthcare challenges of the future.
Market Overview
The MEA regenerative medicine market is categorized into several key regions, including Saudi Arabia, the United Arab Emirates (UAE), South Africa, and the broader Rest of MEA segment. A major health concern in this region is diabetes, which affects around 73 million adults, as reported by the International Diabetes Federation (IDF) in 2021. Additionally, genetic disorders such as sickle cell anemia and beta-thalassemia are prevalent due to the region's diverse genetic background. The ongoing clinical trials for CRISPR-based therapies, such as those conducted by Bluebird Bio for sickle cell disease, underscore the potential for innovative treatments in this area.
Investment in the manufacturing capabilities for cell and gene therapies is on the rise, with both organizations and academic institutions actively engaging in research and development (R&D). Collaborations with Contract Development and Manufacturing Organizations (CDMOs) are becoming more common, bridging the gap between scientific discovery and market readiness.
Market Segmentation
The MEA regenerative medicines market can be segmented by product type, application, and region.
- By Product Type: The market is divided into Cell-Based Products, Gene Therapy, and Tissue Engineering. In 2024, Tissue Engineering is expected to hold the largest market share.
- By Cell-Based Products: This segment includes Stem Cell and Cell-Based Immunotherapy, with Stem Cell products leading the market.
- By Application: The applications of regenerative medicine include Oncology, Neurological Disorders, Wound Healing and Skin Regeneration, Ophthalmology, Orthopedics and Musculoskeletal, Immunology, Genetic Disorders, and others. Oncology is anticipated to dominate this segment in 2024.
The integration of artificial intelligence (AI) into regenerative medicine is revolutionizing the field by enhancing drug discovery processes, personalizing therapies, and expediting development timelines. AI technologies are adept at managing complex biological data and optimizing manufacturing processes, which leads to more efficient regenerative therapies. For instance, Aspen Neuroscience's ANPD-001, currently in Phase II clinical trials for Parkinson's disease, exemplifies how AI can be utilized to reprogram patient skin cells into dopamine-producing neurons. This innovative approach not only ensures the quality of the cells through proprietary AI-based genomic tests but also enhances the safety and personalization of treatments.
Startups are also leveraging AI to advance regenerative medicine. For example, MesencHyal-T from Argentina employs AI-driven cellular therapies for bone regeneration, utilizing machine learning to standardize stem cell expansion and improve their osteogenic potential. Similarly, Trogenix from the UK integrates genomics and machine learning into its viral immunotherapy for targeted regenerative treatments in cancer and age-related tissue repair.
AI platforms are facilitating faster product launches and drug candidate generation. Insilico Medicine, a leader in AI drug discovery, has made headlines with INS018_055, the first entirely AI-discovered medication to enter Phase II trials. Their collaboration with Sanofi, valued at US$ 1.2 billion, showcases the potential of AI in identifying novel therapeutic targets and predicting clinical outcomes.
In manufacturing, companies like Shinobi Therapeutics are utilizing AI to develop immune-evasive induced pluripotent stem cell (iPSC) therapies, which are designed to evade immune detection. This innovation is crucial for creating off-the-shelf regenerative treatments for various conditions, including oncology and autoimmune disorders.
Regional Insights
The MEA regenerative medicines market is further segmented by country, with Saudi Arabia, the UAE, South Africa, and the Rest of MEA being key players. The Rest of MEA, which includes countries like Iran, Iraq, Kuwait, Qatar, Egypt, Kenya, and Israel, held the largest market share in 2024. The increasing prevalence of chronic and degenerative diseases in these nations is driving the demand for regenerative therapies, particularly stem cell treatments that address conditions such as cancer, diabetes, and cardiovascular diseases.
Israel, known for its advancements in biomedical research, is a leader in stem cell and gene therapies, supported by institutions like the Weizmann Institute and Technion. Qatar's focus on genomic research through the Qatar Genome Programme is also noteworthy, as it aims to identify genetic markers for diseases and facilitate the development of targeted therapies. Egypt is making strides in stem cell research, particularly for liver diseases, through institutions like Cairo University.
Conclusion
The regenerative medicine market in the Middle East and Africa is on the cusp of transformative growth, driven by technological advancements, increasing disease prevalence, and strategic collaborations. As the region continues to innovate and invest in regenerative therapies, it is well-positioned to address the healthcare challenges of the future.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. REGENERATIVE MEDICINES MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. REGENERATIVE MEDICINES MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Regenerative Medicines Market Forecast and Analysis
7. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Cell Based Products
7.1.1 Overview
7.1.2 Cell Based Products: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Gene Therapy
7.2.1 Overview
7.2.2 Gene Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Tissue Engineering
7.3.1 Overview
7.3.2 Tissue Engineering: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY CELL BASED PRODUCTS - PRODUCTS TYPE
8.1 Stem Cell
8.1.1 Overview
8.1.2 Stem Cell: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Based Immuno Therapy
8.2.1 Overview
8.2.2 Cell Based Immuno Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Neurological Disorders
9.2.1 Overview
9.2.2 Neurological Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Wound Healing and Skin Regeneration
9.3.1 Overview
9.3.2 Wound Healing and Skin Regeneration: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Ophthalmology
9.4.1 Overview
9.4.2 Ophthalmology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5 Orthopedics and Musculoskeletal
9.5.1 Overview
9.5.2 Orthopedics and Musculoskeletal: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.7 Genetic Disorders
9.7.1 Overview
9.7.2 Genetic Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET - COUNTRY ANALYSIS
10.1 Middle East & Africa
10.1.1 Middle East & Africa Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.1.1 Middle East & Africa Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.2.2 Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 Saudi Arabia: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.1.2.2.2 Saudi Arabia: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.1.2.2.3 Saudi Arabia: Middle East & Africa Regenerative Medicines Market Share - by Application
10.2.3.3 United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 United Arab Emirates: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.2.3.3.2 United Arab Emirates: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.2.3.3.3 United Arab Emirates: Middle East & Africa Regenerative Medicines Market Share - by Application
10.3.4.4 South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 South Africa: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.3.4.4.2 South Africa: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.3.4.4.3 South Africa: Middle East & Africa Regenerative Medicines Market Share - by Application
10.4.5.5 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market Share - by Application
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Novartis AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bristol-Myers Squibb Co
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson & Johnson
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Takeda Pharmaceutical Co Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 BioMarin Pharmaceutical Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 JCR Pharmaceuticals Co. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Daiichi Sankyo Co Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Vertex Pharmaceuticals Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring LLC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Bluebird Bio Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Ferring Pharmaceuticals
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Japan Tissue Engineering Co., Ltd.
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. REGENERATIVE MEDICINES MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. REGENERATIVE MEDICINES MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Regenerative Medicines Market Forecast and Analysis
7. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Cell Based Products
7.1.1 Overview
7.1.2 Cell Based Products: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Gene Therapy
7.2.1 Overview
7.2.2 Gene Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Tissue Engineering
7.3.1 Overview
7.3.2 Tissue Engineering: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY CELL BASED PRODUCTS - PRODUCTS TYPE
8.1 Stem Cell
8.1.1 Overview
8.1.2 Stem Cell: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Based Immuno Therapy
8.2.1 Overview
8.2.2 Cell Based Immuno Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Neurological Disorders
9.2.1 Overview
9.2.2 Neurological Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Wound Healing and Skin Regeneration
9.3.1 Overview
9.3.2 Wound Healing and Skin Regeneration: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Ophthalmology
9.4.1 Overview
9.4.2 Ophthalmology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5 Orthopedics and Musculoskeletal
9.5.1 Overview
9.5.2 Orthopedics and Musculoskeletal: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.7 Genetic Disorders
9.7.1 Overview
9.7.2 Genetic Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST & AFRICA REGENERATIVE MEDICINES MARKET - COUNTRY ANALYSIS
10.1 Middle East & Africa
10.1.1 Middle East & Africa Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.1.1 Middle East & Africa Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.2.2 Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 Saudi Arabia: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.1.2.2.2 Saudi Arabia: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.1.2.2.3 Saudi Arabia: Middle East & Africa Regenerative Medicines Market Share - by Application
10.2.3.3 United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 United Arab Emirates: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.2.3.3.2 United Arab Emirates: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.2.3.3.3 United Arab Emirates: Middle East & Africa Regenerative Medicines Market Share - by Application
10.3.4.4 South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 South Africa: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.3.4.4.2 South Africa: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.3.4.4.3 South Africa: Middle East & Africa Regenerative Medicines Market Share - by Application
10.4.5.5 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market Share - by Product Type
10.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market Share - by Application
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Novartis AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bristol-Myers Squibb Co
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson & Johnson
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Takeda Pharmaceutical Co Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 BioMarin Pharmaceutical Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 JCR Pharmaceuticals Co. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Daiichi Sankyo Co Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Vertex Pharmaceuticals Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring LLC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Bluebird Bio Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Ferring Pharmaceuticals
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Japan Tissue Engineering Co., Ltd.
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
LIST OF TABLES
Table 1. Middle East & Africa Regenerative Medicines Market Segmentation
Table 2. List of Vendors
Table 3. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 6. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 9. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 10. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 12. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 13. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 15. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 16. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 19. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. Heat Map Analysis by Key Players
Table 1. Middle East & Africa Regenerative Medicines Market Segmentation
Table 2. List of Vendors
Table 3. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 6. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 9. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 10. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 12. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 13. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 15. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 16. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 19. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Middle East & Africa Regenerative Medicines Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Middle East & Africa Regenerative Medicines Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Regenerative Medicines Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Cell Based Products: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Gene Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Tissue Engineering: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 11. Middle East & Africa Regenerative Medicines Market Share (%) - by Cell Based Products - Products Type, 2024 and 2031
Figure 12. Stem Cell: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Cell Based Immuno Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Middle East & Africa Regenerative Medicines Market Share (%) - by Application, 2024 and 2031
Figure 15. Oncology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Neurological Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Wound Healing and Skin Regeneration: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Ophthalmology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Orthopedics and Musculoskeletal: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Immunology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Genetic Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Others: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Middle East & Africa Regenerative Medicines Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 24. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
Figure 1. Middle East & Africa Regenerative Medicines Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Middle East & Africa Regenerative Medicines Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Regenerative Medicines Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Cell Based Products: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Gene Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Tissue Engineering: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 11. Middle East & Africa Regenerative Medicines Market Share (%) - by Cell Based Products - Products Type, 2024 and 2031
Figure 12. Stem Cell: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Cell Based Immuno Therapy: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Middle East & Africa Regenerative Medicines Market Share (%) - by Application, 2024 and 2031
Figure 15. Oncology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Neurological Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Wound Healing and Skin Regeneration: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Ophthalmology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Orthopedics and Musculoskeletal: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Immunology: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Genetic Disorders: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Others: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Middle East & Africa Regenerative Medicines Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 24. Saudi Arabia: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. United Arab Emirates: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. South Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Rest of Middle East & Africa: Middle East & Africa Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
